Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances (NASDAQ:TSHA)

Earnings Call InsightsTaysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advancesMar 19, 2026, 6:23 PM ETTaysha Gene Therapies, Inc. (TSHA) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Taysha Gene Therapies (TSHA) Q4 2025 Management View CEO Sean Nolan highlighted 2025 as "a year of significant execution" for Taysha, calling attention to "compelling REVEAL Phase I/II data across pediatric, adolescent and adult patients with Rett syndrome treated wi ...